In 2019, the PIK3CA inhibitor BYL719 (Alpelisib, Novartis) was approved by the FDA for the treatment of estrogen receptor-positive (ER+) breast cancer patients with PIK3CA mutations [152]. The gene discussed is PIK3CA; the disease is breast cancer.